This content is in French.
Targeting IL-23 – a winning bet?
21 mai 2025
#UlcerativeColitis #Mirikizumab #UC #IL23
#Immunotherapy #Gastroenterology
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by continuous inflammation of the recto-colonic mucosa, leading to debilitating symptoms such as abdominal pain, rectal bleeding, chronic diarrhea, and impaired quality of life. Although many therapeutic options have emerged over the past two decades—including anti-TNF agents, anti-integrins, JAK inhibitors, sphingosine-1-phosphate modulators, and ustekinumab—rates of primary failure or secondary loss of response remain high. Up to 50% of patients either do not respond or fail to maintain a long-term therapeutic response. In refractory cases, surgery (colectomy) is still required in about 15% of cases, often resulting in significant functional consequences.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by continuous inflammation of the recto-colonic mucosa, leading to debilitating symptoms such as abdominal pain, rectal bleeding, chronic diarrhea, and impaired quality of life. Although many therapeutic options have emerged over the past two decades—including anti-TNF agents, anti-integrins, JAK inhibitors, sphingosine-1-phosphate modulators, and ustekinumab—rates of primary failure or secondary loss of response remain high. Up to 50% of patients either do not respond or fail to maintain a long-term therapeutic response. In refractory cases, surgery (colectomy) is still required in about 15% of cases, often resulting in significant functional consequences.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Elainein, M. A. A., et al. (2025). Efficacy and safety of Mirikizumab for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. BMC gastroenterology, 25(1), 307
View the source
